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implicates interleukin-6 signalling in the anaemia
of rheumatoid arthritis
John D Isaacs1,5*, Olivier Harari2, Uwe Kobold3, Janet S Lee4 and Corrado Bernasconi2Abstract
Introduction: Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with
haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid
arthritis (RA).
Methods: Data of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated
associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and
iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants
[C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in
haemoglobin level.
Results: At baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After
treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and
haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in
TIBC and haemoglobin.
Conclusions: Inflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement
correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and
increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the
inflammatory anaemia of RA.Introduction
One of the mechanisms of the inflammatory response
is the sequestration of iron in macrophages, leading
to decreased availability of iron to invading pathogens.
Chronic inflammatory diseases—including Castleman’s
disease [1], systemic-onset juvenile idiopathic arthritis [2]
and rheumatoid arthritis (RA) [3]—are often accompanied
by anaemia. Hepcidin acts as a gatekeeper for trans-
membrane iron transport [3], binding to the cellular
iron efflux channel ferroportin, inducing its internalisa-
tion and degradation [4]. Thus, hepcidin inhibits intes-
tinal iron absorption and decreases iron mobilisation* Correspondence: John.Isaacs@newcastle.ac.uk
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reproduction in any medium, provided the orfrom macrophage reticuloendothelial stores [3,5]. Ferritin
scavenges free iron and enables its sequestration in
macrophage reticuloendothelial stores. Haptoglobin de-
creases iron availability in the setting of haemolysis, rather
than inflammation, by scavenging circulating haemoglobin
[6]. Transferrin, the principal iron carrier, regulates the
total iron-binding capacity (TIBC) of blood. Hepcidin, fer-
ritin and haptoglobin are produced in the liver as acute-
phase reactants, and their expression is dependent on
interleukin-6 (IL-6) signalling [3,7,8]. Tocilizumab is a
humanised monoclonal antibody that inhibits IL-6 bin-
ding to its receptor [9].
Tocilizumab reduces hepcidin levels and improves
anaemia in patients with Castleman’s disease [1] and in an
animal model of arthritis [10]. Tocilizumab treatment
is also associated with increased haemoglobin levels in
patients with RA [11-15]. The current analysis tested asso-
ciations between changes in haematological parameterstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tocilizumab in RA (MEASURE) [16,17].
Methods
Patients
This was an exploratory post hoc analysis of data from
MEASURE, a randomised, multicentre, double-blind,
24-week, phase 3B trial with an open-label follow-up
period of two years. Participants were 18 years of age or
older and had moderate to severe active RA of more
than six months duration and inadequate responses to
methotrexate (MTX). They had ≥6 swollen and tender
joints, with either C-reactive protein (CRP) >10 mg/L or
erythrocyte sedimentation rate (ESR) ≥28 mm/hour at
screening and were randomly assigned 1:1 to receive
tocilizumab 8 mg/kg intravenously (IV) or placebo every
four weeks plus weekly MTX. For the current analysis,
patients were analysed according to the treatment they
received during the first 12 weeks of the study (that is,
before rescue therapy was permitted per protocol). The
study was approved by independent ethics committees
outside the United States (approval was obtained from a
local review board; if there was no local review board,
approval was obtained from a regional committee; if
there was no regional committee, approval was obtained
from the European Ethics Review Committee) and insti-
tutional review boards in the United States, and all sub-
jects consented in writing to participation. A full listing
of ethics committees and institutional review boards is
available in Additional file 1: Table S1.
Assessments
Serum hepcidin was measured by high-performance liquid
chromatography–tandem mass spectroscopy assay [18].
Serum haptoglobin was determined using a Roche Diag-
nostic immunoturbidimetric assay kit. Anti-haptoglobin
antibodies mixed with sample produced immunocom-
plexes that were quantified using the Roche Modular P
autoanalyser (Roche Diagnostics, Mannheim, Germany)
and detection at 340 nm. Markers of inflammation and
iron homeostasis were measured using standard available
assays. Assessments were performed at screening, base-
line, day 1 and weeks 1, 2, 4, 8, 12 and 24 during rando-
mised treatment.
Statistical analysis
Descriptive statistical methods and univariate and multi-
variate linear regression were used. Specific regression
models were refined using a statistical selection proce-
dure: successive variable elimination based on Akaike’s
Information Criterion. Because of the distribution of raw
values, logarithmic transformation was used for high-
sensitivity CRP, hepcidin and ferritin values in statistical
models. In addition, in correlation analyses, Pearson’scoefficient was complemented with the non-parametric
Spearman’s rank correlation.
Results
Patients
The study enrolled 132 patients; 63 were randomly
assigned to placebo +MTX (control) and 69 to toci-
lizumab +MTX. One patient assigned to placebo received
tocilizumab from study start and was evaluated in the
tocilizumab group for the current analysis. Mean age was
slightly higher in this study than in the tocilizumab phase
3 pivotal trials; however, disease characteristics were simi-
lar [11-15]. Baseline demographics and disease charac-
teristics were generally similar between patients in the
tocilizumab and the control groups (Additional file 2:
Table S2). The median age of patients in both groups was
57.0 years. A slightly higher proportion of patients in the
tocilizumab group were women (83% and 74%, res-
pectively), and they had slightly higher CRP at baseline
(median, 12.5 and 10.4 mg/L). The median duration of
RA at baseline was similar between groups (7.0 years
(tocilizumab) versus 6.8 years (control)), as were Disease
Activity Scores using 28 joints (DAS28) (6.8 (tocilizumab)
versus 6.6 (control)). Overall, 7.1% of tocilizumab and
11.3% of placebo patients had anaemia at baseline by
World Health Organization criteria (haemoglobin: <11 g/dl
(women), <12 g/dl (men)).
Baseline parameters and correlations
Haemoglobin levels at baseline exhibited modest inverse
correlations with the acute-phase reactants CRP and hapto-
globin (Spearman rank correlation [ρ] = −0.20 and −0.25,
respectively; P = 0.023 and P = 0.004, respectively) and
only minimal correlation with IL-6 (Additional file 3:
Figure S1). Pretreatment hepcidin was highly variable
(0 to 63.1 fmol/μl; coefficient of variation (CV) 1.2)
(Additional file 4: Figure S2). CVs were lower for ferritin
(0.86), haptoglobin (0.43) and TIBC (0.17). Haemoglobin
did not correlate with hepcidin (Additional file 5: Figure S3)
or TIBC. Ferritin and haemoglobin levels had a weak posi-
tive association, with the effect more pronounced at very
low ferritin levels. There was also a trend towards low
mean corpuscular volume (MCV) with low ferritin.
Hepcidin levels significantly correlated with haemoglo-
bin homeostasis markers ferritin (ρ = 0.64) and TIBC
(inversely; ρ = −0.34) and also with IL-6, CRP and
haptoglobin (ρ = 0.34-0.46; P ≤0.001) (Additional file 5:
Figure S3).
Longitudinal effect of tocilizumab
Increases in haemoglobin levels and early reductions in
hepcidin, CRP, haptoglobin and ESR were observed in
association with tocilizumab therapy (n = 70) (Figure 1).
A rapid decline in hepcidin level was apparent from day
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Figure 1 Time course of median percentage change in (A) haematological and (B) inflammatory markers. Patients received tocilizumab +MTX.
TIBC, total iron-binding capacity. MTX, methotrexate.
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shown), CRP and haptoglobin levels were detectable by
week 1. Haemoglobin levels increased by week 4 and
increased further to week 12, reaching a plateau by week
24 (data not shown). Ferritin levels fell and TIBC in-
creased with kinetics similar to those of haemoglobin
(Figure 1).
Longitudinal relationships
In tocilizumab-treated patients, an early decline in hep-
cidin level (mean of decline at weeks 1 and 2 for each
patient) correlated with a subsequent increase in haemo-
globin level (at weeks 4, 8 and 12) (ρ >0.31 and P <0.011
for all comparisons) (Figure 2). These effects were not
evident for the placebo group, as indicated in Figure 2
and by a significant interaction between treatment group
assignment and hepcidin change (P = 0.023) in models of
the haemoglobin change adjusted for baseline haemoglo-
bin. Therefore, further evaluations of treatment-related
longitudinal effects were performed in the tocilizumab
group only. Furthermore, a decline in CRP and hapto-
globin level at week 2 correlated with a week 12 increase
in haemoglobin level (ρ >0.33 and P <0.026 for all com-
parisons) (Additional file 6: Figure S4). In multivariate
analyses, patient-to-patient variability in haemoglobinincrease through week 12 remained largely unexplained,
but the strongest association was with a fall in haptoglo-
bin (multiple r2 = 0.29; P <0.0033) (Table 1). This effect
remained evident in analyses limited to patients with
baseline haemoglobin levels below the median (multiple
r2 = 0.49; P = 0.0018).
Discussion
The iron-sequestering actions of hepcidin are hypo-
thesised to be the major determinant of inflammatory
anaemia [3,19]. In support of this mechanistic under-
standing, tocilizumab induced rapid and sustained
decreases in hepcidin that were associated with subse-
quent increases in haemoglobin. At baseline, hepcidin
levels were inversely correlated with TIBC, underscoring
the role of hepcidin in reducing iron bioavailability.
Ferritin, hepcidin and haptoglobin at baseline correlated
with ESR, CRP and IL-6 (Additional file 5: Figure S3).
This underscores their behaviour as acute-phase reac-
tants, as does the correlation between ferritin and hep-
cidin. The rapid declines in their levels after tocilizumab
treatment were consistent with IL-6 signalling being a
common stimulus to their production. At baseline, there
was a weak inverse correlation between haemoglobin
and the acute-phase reactants but no association with
Table 1 Multivariate analysis of tocilizumab-induced
increases in haemoglobin at week 12
Statistical model Coefficient SE P
Basic linear model in the tocilizumab arma
Intercept 2.20 1.93 0.26
Baseline haemoglobin, g/dl −0.19 0.14 0.20
Change log(CRP) baseline, week 2 −0.048 0.15 0.75
log(Hepcidin) change from baseline
to week 2, fmol/μl
−0.044 0.11 0.69
Haptoglobin change from baseline
to week 2, fmol/μl
−0.0052 0.0028 0.076
Male 0.042 0.45 0.93
Refined multivariate modelb
Intercept 2.20 1.68 0.20
Baseline haemoglobin, g/dl −0.18 0.12 0.15
log(Haptoglobin) change from baseline
to week 2, fmol/μl
−0.0060 0.0021 0.0079
aMultiple r2 = 0.30, P = 0.047; bMultiple r2 = 0.29, P < 0.0033. CRP, C-reactive
protein; SE, standard error.
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Figure 2 Scatter plot and linear regression of haemoglobin level at week 12 versus log hepcidin. Change from baseline in haemoglobin
level (g/dl) at week 12 versus mean of change from baseline at weeks 1 and 2 in log hepcidin (fmol/μL). (A) Placebo: r2 = 0.002; P = 0.76;
Spearman rank correlation: ρ = 0.04, P = 0.79. (B) Tocilizumab: r2 = 0.09; P = 0.012; Spearman rank correlation: ρ = −0.35, P = 0.005. aMean of weeks
1 and 2 assessments.
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line hepcidin.
Nevertheless, this underscores the current understan-
ding of the relationship between hepcidin and haemoglo-
bin as an indirect one, mediated through the regulation
of iron transport. Tocilizumab had an immediate and pro-
found effect on hepcidin levels, whereas its effect on
haemoglobin was slower; the acute-phase reactants—
haptoglobin, in particular—showed an intermediate
kinetic. The more similar kinetics of haptoglobin and
haemoglobin changes might have strengthened their asso-
ciation compared with those of hepcidin and haemoglo-
bin. However, because this was a post hoc analysis of
clinical trial data, the ability to assess causal relationships
is limited. This is a limitation of the study, which focuses
on the strength of associations but cannot elucidate the
structure of the interaction network. Although reductions
in hepcidin clearly influence subsequent increases in
haemoglobin level, we cannot exclude other influences on
haemoglobin levels. The observation that a small subset of
patients with the lowest ferritin levels also had low
haemoglobin levels and low MCV indicates that in these
patients, iron deficiency might have been driving anaemia
more than inflammation. However, the number of such
patients appears too small to have impacted the relation-
ship between tocilizumab treatment and resolution of
inflammatory anaemia evident in the overall population.
The MEASURE study population had a relatively modest
baseline CRP elevation in spite of moderate to high
DAS28 scores, so it is possible that the associations
reported here would have been more marked in a cohort
of patients with higher levels of systemic inflammation
and lower levels of haemoglobin. Patients assigned totocilizumab had slightly higher CRP levels and DAS28
scores but also slightly higher haemoglobin levels than
those assigned to placebo. Although the differences were
not great enough to affect the results, the counterintuitive
directionality of inflammation versus anaemia underscores
the variability associated with these parameters, even in a
study of more than 100 patients.
The overall pattern of normalisation in haematological
parameters engendered by tocilizumab is in keeping with
previous reports with this therapy in Castleman’s disease
[1] and strongly supports a role for IL-6 in the inflam-
matory anaemia of RA. To dissect the influence of
Isaacs et al. Arthritis Research & Therapy 2013, 15:R204 Page 5 of 6
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an appropriately powered study specifically in anaemic
RA patients, with a purposely designed sampling scheme
and an examination of the influence of other therapies.
Conclusions
In patients with RA treated with tocilizumab, reductions
in inhibitors of iron transport and availability, hepcidin
and haptoglobin, as well as the acute-phase reactant CRP,
were associated with subsequent increases in haemo-
globin. Therefore, inflammatory anaemia in RA appears
to involve IL-6 signalling and improves with tocilizumab
treatment.
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Additional file 2: Table S2. Baseline demographics, disease and
haematologic factors.
Additional file 3: Figure S1. Scatter plot and linear regression for
baseline haemoglobin versus log baseline CRP, haptoglobin and IL-6.
(A) Baseline haemoglobin versus log baseline CRP (mg/dl). (B) Baseline
haemoglobin versus baseline haptoglobin (mg/dl). (C) Baseline
haemoglobin versus log baseline IL-6 (pg/ml). (A) r2 = −0.18, P = 0.039;
Spearman rank correlation: ρ = −0.20, P = 0.023. (B) r = −0.27, P = 0.0015;
Spearman rank correlation: ρ = −0.25, P = 0.004. (C) r2 = −0.15, P = 0.15,
Spearman rank correlation: ρ = −0.19, P = 0.048. CRP, C-reactive protein.
Additional file 4: Figure S2. Levels of hepcidin (fmol/μl). (A) Baseline.
(B) Week 1.
Additional file 5: Figure S3. Scatter plots and linear regression of
baseline hepcidin versus baseline ferritin, CRP, haptoglobin and
haemoglobin. Baseline hepcidin versus baseline (A) ferritin, (B) CRP,
(C) haptoglobin and (D) haemoglobin levels. (A) r2 = 0.47, ρ = 0.64,
P <0.0001. (B) r2 = 0.11, ρ = 0.34, P = 0.0001. (C) r2 = 0.24, ρ = 0.45,
P <0.0001. (D) r2 = 0.004, ρ = 0.34, P <0.49.
Additional file 6: Figure S4. Scatter plot and linear regression of
change from baseline in haemoglobin level (g/dl). Change from baseline
in haemoglobin level (g/dl) at week 12 versus mean of change from
baseline at weeks 1 and 2 in log CRP (mg/dl) and haptoglobin (mg/dl).
(A) r2 = −0.31, P = 0.040; ρ = −0.33, P = 0.026. (B) r2 = −0.44, P <0.001;
ρ = −0.43, P <0.001.
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